During the fourth quarter, Ngenic entered several partnership agreements, received a breakthrough order, and scaled up its capacity. While recognizing that the company's cash balance was cSEK11m at year-end, we are maintaining our fair value range and base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ngenic Q4 2022 - Review

© Modular Finance, source Nordic Press Releases